- Home
- Clinical Trials
Atrial Fibrillation Studies Brisbane
Roxi-Incline Atrial Fibrillation Study
Taringa Brisbane
Do you have atrial fibrillation (an irregular heartbeat)? This condition can increase your cardiovascular risk. You may be suitable to join a clinical study to explore an investigational medication for people who cannot take standard blood-thinning medicines for Atrial Fibrillation.
By taking part, you may help progress the understanding of atrial fibrillation, receive regular health assessments, and help advance medical research.
Description
What to expect
Study details
Ages
18 years or older
Duration
The study duration is approximately 15 to 39 months, with regular clinic visits (every 2 weeks)
Compensation
Participants will be paid for time and study-related costs.
Eligibility Criteria
You may be suitable for this study if you:
- Are aged 18 years or older
- Have been diagnosed with atrial fibrillation (irregular heartbeat) or atrial flutter
- Have been advised that blood-thinning medication may not be suitable for you
- Are at higher risk of stroke (e.g., ≥75 years of age, or have had a previous stroke or TIA)
Other criteria will apply.
Locations
Description
Atrial fibrillation (also known as AF) is a common heart condition that causes an irregular or uneven heartbeat. This can affect how well the heart pumps blood around the body. As a result, some people may experience symptoms such as a racing or fluttering heartbeat, shortness of breath, tiredness, dizziness, or reduced ability to exercise.
AF can have a significant impact on daily life, particularly if symptoms are frequent or ongoing. In some cases, people may not notice any symptoms at all, but the condition can still increase the risk of serious health problems.
One of the main concerns with AF is the increased risk of blood clots forming in the heart. These clots may travel to the brain and cause a stroke, or lead to other cardiovascular complications such as heart failure. For this reason, many people with AF are prescribed blood-thinning medications to help reduce the risk of stroke. While these treatments can be effective, they are not suitable for everyone. Blood-thinning medicines can increase the risk of bleeding, which may be a concern for some individuals, particularly those with certain medical conditions or a history of bleeding.
This study aims to investigate a potential approach that may offer an alternative for people who are unable to take standard blood-thinning medications. The study medication is designed to potentially reduce cardiovascular risk in people with AF.
Please note that this clinical trial will use an investigational drug product, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities, and which has not received marketing authorization in any country.
What to expect
If suitable, you will be enrolled into the study and will receive either one of the study medications or a placebo, which is given as an injection under the skin (SC injection). You will have a 1 in 3 chance of receiving the Placebo. Study treatments will be given approximately every 2 weeks.
You will attend regular clinic visits for health assessments, including physical measurements, blood tests, and general health check-ups.
Your safety and wellbeing will be closely monitored by our experienced clinical team throughout the study.
Why join a clinical research study?
- Potentially gain early access to an investigational medication at no cost
- Contribute to the understanding of atrial fibrillation
- Receive health checks and advice from our professional medical team
Your privacy is important. All personal information will be kept strictly confidential. Your involvement may provide crucial data that could lead to advancements in Atrial Fibrillation.
Register your interest today!
Apply Now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research AU is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. By clicking 'Submit' you agree to our Privacy Policy which contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.